Amipaque: a new contrast medium in coronary angiography. Report of a double-blind study in man.
Isopaque Coronar and Amipaque (metrizamide) were evaluated in a comparative double-blind study of 30 patients with heart disease undergoing selective coronary angiography. Amipaque alone was also used for 9 additional patients undergoing left ventriculography, aortic root injection, and selective coronary angiography. Amipaque resulted in significantly less of a decrease in diastolic pressure and heart rate, reduced chest pain and heat sensation, and longer coronary contrast transit time. Electrorocardiographic parameters and image quality were equivalent with the 2 agents. No pathological changes were noted in the 9 patients undergoing complete angiocardiographic study.
D000328:Adult; D000368:Aged; D000792:Angiography; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007463:Iodobenzoates / Q000494:pharmacology; D008297:Male; D008793:Metrizamide / Q000494:pharmacology; D008794:Metrizoic Acid / Q000494:pharmacology; D008875:Middle Aged
D007463:Iodobenzoates; D008794:Metrizoic Acid; D008793:Metrizamide